Genus (FRA:GBE) Gross-Profit-to-Asset % : 64.61% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Genus Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Genus's annualized Gross Profit for the quarter that ended in Dec. 2023 was €774.5 Mil. Genus's average Total Assets over the quarter that ended in Dec. 2023 was €1,198.7 Mil. Therefore, Genus's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 64.61%.

Genus Gross-Profit-to-Asset % Historical Data

The historical data trend for Genus's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genus Gross-Profit-to-Asset % Chart

Genus Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

20.61

26.75

26.00

23.04

23.63

Genus Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															64.72	64.93	68.15	67.30	64.61

Competitive Comparison of Genus's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Genus's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genus's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genus's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Genus's Gross-Profit-to-Asset % falls into.

Genus Gross-Profit-to-Asset % Calculation

Genus's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	278.881	/	( (1185.879	+	1174.145)	/ 2 )
	=	278.881	/	1180.012
	=	23.63 %

Genus's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	774.458	/	( (1174.145	+	1223.324)	/ 2 )
	=	774.458	/	1198.7345
	=	64.61 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Genus Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Genus's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genus (FRA:GBE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (FRA:GBE) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

GENSF:USA GNSl:UK GNS:UK

Address

Matrix House, Basing View, Basingstoke, Hants, GBR, RG21 4DZ

Website

https://www.genusplc.com

Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.

Genus (FRA:GBE) Headlines

No Headlines